Clinical trials: Peritoneal Cavity Cancer
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase II trial studies how well bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that has come back or is…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01305213
- Testing
- Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00217529
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Chemotherapy-induced Peripheral Neuropathy, Recurrent Ovarian Carcinoma
High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy
This study aims to evaluate the safety and efficacy of high dose inorganic selenium in preventing and relieving chemotherapy-induced peripheral neuropathy (CIPN) in platinum-sensitive recurrent ovarian, fallopian, or primary…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Recurrent Ovarian Carcinoma, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- SELENIUM (NCT04201561)
- Testing
- sodium selenite pentahydrate, Normal saline, Chemotherapy
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Fallopian Tube Cancer, Ovarian Cancer
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00838656
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 4 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Warwick Medical School
Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer
Women with history of tumor response insufficient to allow complete cytoreductive surgery after three cycles of previous neoadjuvant systemic carboplatin-paclitaxel chemotherapy will be prospectively recruited in this trial.
- Conditions
- Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis, Stage III Ovarian Cancer, Stage III Fallopian Tube Cancer
- Trial name
- PIPACOVA (NCT04811703)
- Testing
- Combined PIPAC / IV chemotherapy treatment
- Where
- 6 sites in France
- Volunteers
- 15 people
- Sponsor
- Hospices Civils de Lyon
Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
This is a Phase 1b/2, open-label, 2-part, global study designed to investigate the anti-tumor activity as well as the safety and efficacy of BAT8006 in subjects with platinum resistance ovarian cancer
- Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06545617
- Testing
- BAT8006 for Injection
- Sponsor
- Bio-Thera Solutions
Fallopian Tube Carcinoma, Ovarian Carcinoma
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This research trial studies biomarkers in patients with previously untreated invasive ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01295489
- Testing
- Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Peritoneal Neoplasms
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Background: Birinapant is an experimental cancer treatment drug. It removes certain proteins in cells, which helps to kill the cells.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01681368
- Testing
- Birinapant (TL32711)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the leading cause of gynecological malignancy-related deaths worldwide and is a substantial health threat to women.
- Conditions
- Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- Trientine (NCT03480750)
- Testing
- trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin
- Volunteers
- 18 people
- Sponsor
- National Cheng-Kung University Hospital
Epithelial Ovarian Cancer, Peritoneal Cancer
Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT
The purpose of this study is to determine, whether there is clinical benefit of using fdg-PET/CT (F-18-fluorodeoxyglucose- positron emission tomography/computed tomography)compared to contrast-enhanced CT in primary treatment of…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- Mupet (NCT01276574)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Turku University Hospital